VEGF inhibitors

Ariel Lopez Chavez, Alan Sandler

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Angiogenesis is a fundamental step in the development and progression of malignant tumors. Blockade of angiogenesis in preclinical models prevents the growth of tumor cells and therefore tumor progression. The VEGF pathway is considered to be the major regulator of angiogenesis in normal and malignant tissues. Bevacizumab is the only angiogenesis inhibitor currently approved for use in advanced nonsmall-cell lung cancer. A paclitaxel-based regimen in combination with bevacizumab is the only regimen that has demonstrated a survival advantage in comparison to standard chemotherapy in a Phase III trial. There is a lack of reliable prognostic or predictive biomarkers for selecting patients with nonsmall-cell lung cancer who would benefit from antiangiogenic therapy.

Original languageEnglish (US)
Title of host publicationTargeted Therapies for Non-Small-Cell Lung Cancer
PublisherFuture Medicine Ltd.
Pages35-45
Number of pages11
ISBN (Print)9781780840468, 9781780841236
DOIs
StatePublished - Oct 1 2012
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chavez, A. L., & Sandler, A. (2012). VEGF inhibitors. In Targeted Therapies for Non-Small-Cell Lung Cancer (pp. 35-45). Future Medicine Ltd.. https://doi.org/10.2217/EBO.12.8